Iovance Biotherapeutics, Inc.
IOVA
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candiā¦ read more
Healthcare
Biotechnology
15 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.48
Price+0.81%
$0.02
1Y
Price
Market Cap
$822.588m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-125.5%
EBITDA Margin-135.3%
Net Profit Margin-132.7%
Free Cash Flow MarginRevenue
$250.425m
+52.6%
1y CAGR+4583.9%
3y CAGR+3437.9%
5y CAGREarnings
-$397.633m
-6.8%
1y CAGR-0.9%
3y CAGR-4.6%
5y CAGREPS
-$1.20
+6.3%
1y CAGR+20.9%
3y CAGR+12.7%
5y CAGRBook Value
$702.287m
$904.948m
Assets$202.661m
Liabilities$52.492m
DebtDebt to Assets
5.8%
-0.1x
Debt to EBITDAFree Cash Flow
-$351.823m
+3.4%
1y CAGR-4.7%
3y CAGR-8.0%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company